加载中
Dogwood Therapeutics, Inc. is an emerging biotechnology firm dedicated to creating innovative antiviral treatments. Their primary goal is to address illnesses that stem from atypical immune reactions provoked by viral infections. Its leading therapeutic candidate, IMC-1, is a precise fixed-dose combination of famciclovir and celecoxib, engineered to combat fibromyalgia. Additionally, the company is advancing IMC-2, which blends valacyclovir and celecoxib, aiming to alleviate the array of symptoms linked to long COVID, including persistent fatigue, sleep disturbances, cognitive issues, pain, autonomic dysfunction, and anxiety. Previously operating as Virios Therapeutics, Inc., the organization adopted the name Dogwood Therapeutics, Inc. in October 2024. Established in 2012, the company maintains its main office in Alpharetta, Georgia.
前收盘价
US$1.43
−US$0.09 · -5.92%
盘前
US$1.51
+US$0.08 · +5.59%
10月8日 9:14 ET
盘中时间采用ET。市场数据可能有所延迟。
Dogwood Therapeutics, Inc. is an emerging biotechnology firm dedicated to creating innovative antiviral treatments. Their primary goal is to address illnesses that stem from atypical immune reactions provoked by viral infections. Its leading therapeutic candidate, IMC-1, is a precise fixed-dose combination of famciclovir and celecoxib, engineered to combat fibromyalgia. Additionally, the company is advancing IMC-2, which blends valacyclovir and celecoxib, aiming to alleviate the array of symptoms linked to long COVID, including persistent fatigue, sleep disturbances, cognitive issues, pain, autonomic dysfunction, and anxiety. Previously operating as Virios Therapeutics, Inc., the organization adopted the name Dogwood Therapeutics, Inc. in October 2024. Established in 2012, the company maintains its main office in Alpharetta, Georgia.
日内区间
当前US$1.43
52周区间
当前US$1.43
盘中时间采用ET。市场数据可能有所延迟。
Dogwood Therapeutics, Inc. is an emerging biotechnology firm dedicated to creating innovative antiviral treatments. Their primary goal is to address illnesses that stem from atypical immune reactions provoked by viral infections. Its leading therapeutic candidate, IMC-1, is a precise fixed-dose combination of famciclovir and celecoxib, engineered to combat fibromyalgia. Additionally, the company is advancing IMC-2, which blends valacyclovir and celecoxib, aiming to alleviate the array of symptoms linked to long COVID, including persistent fatigue, sleep disturbances, cognitive issues, pain, autonomic dysfunction, and anxiety. Previously operating as Virios Therapeutics, Inc., the organization adopted the name Dogwood Therapeutics, Inc. in October 2024. Established in 2012, the company maintains its main office in Alpharetta, Georgia.
日内区间
当前US$1.43
52周区间
当前US$1.43
营业利润
净利润
| 项目（USD） | 2025财年 | 2024财年 | 2023财年 | 2022财年 | 2021财年 |
|---|---|---|---|---|---|
| 研究与开发 | 2186.61万 USD | 353.09万 USD | 172.81万 USD | 806.96万 USD | 1079.57万 USD |
| 销售、一般及管理费用 | 610.24万 USD | 869.63万 USD | 371.88万 USD | 424.57万 USD | 484.53万 USD |
| 营业费用 | 2796.84万 USD | 1222.72万 USD | 544.69万 USD | 1231.53万 USD | 1564.09万 USD |
| 利息收入 | 9.69万 USD | — | 15.09万 USD | 6.75万 USD | 5672 USD |
| 利息支出 | — | 9.22万 USD | — | — | — |
| 折旧和摊销 | 2063 USD | 1.22万 USD | — | — | — |
| 营业利润 | −2796.84万 USD | −1222.72万 USD | −544.69万 USD | −1231.53万 USD | −1564.09万 USD |
| 净利润 | −3425.74万 USD | −1234.97万 USD | −529.6万 USD | −1224.78万 USD | −1596.03万 USD |
公司数据更新于 2026年10月8日。
近期已公布业绩
报告持有此股票敞口的交易所交易基金。
AI 生成内容及延迟市场数据仅供信息与教育用途，不构成投资建议。
